Abstract: This packaging device comprises a first stage (2a) of supporting units (20) configured to support a first plurality of medical containers (100a) in a first plane, a second stage (2b) of supporting units (20) configured to support a second plurality of medical containers (100b) in a second plane parallel to said first plane, the first plane and the second plane being spaced apart from each other so that the distal ends (106) of the first plurality of medical containers (100a) extend between medical containers of the second plurality of medical containers (100b), and the supporting units (20) of the first and second stages (2a, 2b) being configured so that the medical containers of the first and second pluralities of medical containers (100a, 100b) are oriented in a same direction. The first stage (2a) of supporting units (20) is formed by a first plate-shaped nest and the second stage (2b) of supporting units (20) is formed by a second plate-shaped nest.

Abstract: According to the preferred embodiment, as depicted in FIG. 1, at least two medication containers (16). A label (32) with indicia (33) and medication-related information (29) is attached to the flat surface (28) of medication containers (16). Indicia (33) and medication-related information (29) of one of said medication containers (16) align and correspond with indicia (33) and medication-related information (29) of the other said medication container (16), and also align with the indicia (33) and medication-related information (29) of any other medication containers (16) that the user may necessitate for storing additional medications. Accordingly, the user will be able to observe medication-related information (29) and indicia (33) of one medication container (16) continuously across medication-related information (29) and indicia (33) of one other medication container, or of several other medication containers (16).

Abstract: Example implementations relate to a drug dispenser. For example, a dispenser may include a processor in communication with a server accessible to a doctor capable of prescribing a drug to a patient and a pharmacist capable of providing the drug to the patient. The processor may receive instructions relating to administration of the drug to the patient. The instructions may specify a timing and an amount of the drug to be administered and an identity of the patient. The dispenser may include a timer to provide a notification based on the timing specified in the instructions and an identifier mechanism to determine an identity of a person attempting to access the drug. The processor may provide the amount of the drug based on the instructions if the identity of the person is the identity of the patient.

Abstract: The present invention relates to a method for preparing solid microcapsules that comprises of the following steps: a) the preparation of a composition C1, comprising at least one water-soluble or hydrophilic substance dispersed in a hydrophobic phase; b) the addition, under stirring, of the said composition C1 in a polymeric composition C2, the compositions C1 and C2 being immiscible with each other, whereby an emulsion (E1) is obtained; c) the addition, under stirring, of the emulsion (E1) in a composition C3, the compositions C2 and C3 being immiscible with each other, whereby a double emulsion (E2) is obtained; d) the application of a shear to the emulsion (E2), whereby a double emulsion (E3) is obtained; and e) the polymerisation of the composition C2, whereby solid microcapsules dispersed in the composition C3 are obtained.

Abstract: Reduced-ethanol perfume compositions according to the invention comprise specific combinations of acrylates/VA copolymer and acrylates copolymer in an aqueous base or delivery vehicle. The perfume compositions according to the invention are easy to manufacture and provide an aqueous perfume composition that preserves aromatic integrity (intensity, duration and range), even in emulsion form. The most advantageous use of compositions of the invention are as parfums, eau de parfums, eau de toilettes, and colognes. However, the invention may also find use in many types of fragranced products, such as those used on the skin and hair of humans or animals, in cleaning products of all types, in air deodorizers, air fresheners, and more.

Abstract: The subject matter of the invention is a method for producing a formulation containing ceramide, comprising the method steps: A) Melting a mixture containing at least one wax and at least one ceramide, B) Cooling the melted mixture to obtain a solidified melt containing the at least one wax and the at least one ceramide, C) Incorporating the solidified melt into a formulation containing oil. The invention also relates to the solidified melt of the aforementioned mixture.

Abstract: The present disclosure provides a powder-containing water-based composition having high powder dispersibility and stability even when the content by percentage of powder is high, and also having little stickiness. The powder-containing water-based composition includes (A) an aqueous phase constituting a continuous phase, (B) 10 to 45% by mass of a powder, and (C) 0.7% by mass or greater of a thickener. The thickener is a polymer that includes, as a constituent component, 2-acrylamido-2-methylsulfonic acid or a salt thereof. A content of an oily component is 15% by mass or less relative to the mass of the composition.

Abstract: Disclosed is an oil-in-water emulsion composition, and a preparation method therefor, and a product, wherein the composition comprises: a) cellulose with a hydrophobic group; b) a surfactant; c) a higher alcohol; d) an oil component; e) water; and optionally, f) a humectant and/or g) a higher fatty acid; the composition has a viscosity of 10,000 mPa·s or less.

Abstract: The present invention provides a water-in-oil emulsion composition having a high water occlusive of a coating film and having good skin protective feeling and glossiness. The water-in-oil emulsion composition is provided containing the following components (A), (B), (C), (D) and (E): (A) 1% by mass or more and 15% by mass or less of a lipophilic surfactant having an HLB of 2-6; (B) 0.15% by mass or more and 8% by mass or less of a dextrin fatty acid ester having 8-22 carbon atoms in the fatty acid moiety; (C) 1% by mass or more and 20% by mass or less of one or more oily components selected from a dimer acid ester, a fatty acid cholesterol ester having 16-22 carbon atoms, a fatty acid phytosterol ester having 16-22 carbon atoms, and an N-acyl amino acid ester; (D) a hydrocarbon oil that is liquid at 25° C.; and (E) water.

Abstract: The invention relates to a nail varnish composition comprising: a) an embossed effect pigment comprising a metallic substrate in platelet form with embossed structure having a periodic pattern with diffractive elements, said substrate having been produced by PVD methods, and optionally at least one coating applied to the substrate, wherein the substrate has an elemental metal content of 80% to 100% by weight, based on the substrate, and wherein the effect pigment has been treated with a leafing additive for surface modification, b) at least one hydrocarbon resin as binder, c) at least one solvent or solvent mixture and d) optionally further auxiliaries. The invention further relates to a process for producing the nail varnish composition.

Abstract: A product comprising a zinc oxide nanoparticle onto which one or more natural odor neutralizers are adsorbed. The product can be used as a component of an oral care product such as a mouthwash, a mouth rinse, a toothpaste, a mint, a chewing gum, or as a component of a personal care product.

Abstract: The invention provides a cosmetic having strong resistance to contact with water, clothing, fingers, and abrasion with little decline (post-contact) in the cosmetic effects such as UV blocking protection as well as excellent feel on use. The cosmetic contains: (A) plate-shaped powder, (B) 6-40% by mass UV absorber, and (C) cationic surfactant.

Abstract: The present invention relates to an antimicrobial composition at the pH of the skin. Particularly, it relates to an antimicrobial composition comprising water soluble vinyl polymer, a carboxylic acid having pKa greater than 4.5; and an anionic surfactant, wherein the composition has pH in the range 4.5 to 6.5. The compositions provides synergistic antimicrobial effect in relatively shorter contact time. The invention further relates to a method of disinfecting a surface using the composition.

Abstract: This invention relates to a topical, cosmetic or dermatological composition, comprising a 1,3 diglyceride having the general formula (I), in which the radicals R1 and R2 represent, independently of one another, a C13 to C40 saturated and linear alkyl radical, and at least one cosmetic or dermatological excipient for a topical application on the skin. This invention also relates to such a composition, or a 1,3 diglyceride having the formula (I), for its use in protecting the skin, in countering the weakening of the skin barrier and in preventing or reducing the penetration of exogenous molecules into the skin following a weakening of the skin barrier.

Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.

Abstract: The present invention relates to a process for dyeing keratin fibres, in particular human keratin fibres such as the hair, using one or more particular azinium dyes and one or more fluorescent dyes. The present invention also relates to a cosmetic composition comprising the dyes defined above, and also to a multi-compartment device containing said dyes. The present invention also relates to the use of said dyes for dyeing light keratin fibres, especially human keratin fibres such as the hair, in chestnut-brown, dark chestnut-brown, brown, brown with a glint, or even black, without using an additional dye other than those defined above.

Abstract: A powder hair dye composition, containing the following components (A) to (C): (A) one or more azo dyes selected from the group consisting of the following (A-1), (A-2) and (A-3), (B) an alkaline agent other than alkanolamines, and (C) 1.5 mass % or more and 40 mass % or less of solvent.

Abstract: The invention relates to resorcinol-based compounds of formula (I), to the salts, solvates, optical and/or geometrical isomers thereof, to the use thereof as active agents for depigmenting, lightening and/or bleaching keratin materials, and/or for preventing, reducing and/or treating impairment of the skin complexion or of the colour of the semi-mucous membranes. The invention also relates to a non-therapeutic cosmetic treatment process for depigmenting, lightening and/or bleaching keratin materials, and/or for preventing, reducing and/or treating impairment of the skin complexion or the colour of the semi-mucous membranes.

Abstract: The present disclosure relates to a cosmetic composition for blocking fine dust. The composition according to the present disclosure can fundamentally prevent problems due to fine dust by reducing the attachment rate of fine dust attached to skin.

Abstract: Personal care compositions including a naringin:zinc complex and methods for preparing and using the same are provided. The personal care compositions may include a carrier and a naringin:zinc complex having a 2:1 naringin to zinc molar ratio.

Abstract: The present invention relates to phytosphingosine-1-phosphate micelle nanoparticles having high transdermal penetration and absorption rates. In addition, the present invention relates to a cosmetic composition containing the micelle nanoparticles and a skin care method using the same.

Abstract: The present invention relates to a mousse composition including water, at least one C2-C5 alcohol, at least one salt, at least one amphiphilic polymer, and at least one hydrophobic surface-treated pigment, as well as to methods for making-up and enhancing the appearance of keratinous materials using the mousse composition.

Abstract: Composition and emulsifier system comprising mixtures of alkoxylated fatty alcohols for use in emulsifying formulations, in particular formulations in personal care. In particular the composition and emulsifier system provide emulsification under extreme conditions such as high salt content, low/high pH, or under high temperatures.

Abstract: A cosmetic including at least one cyclic silicone represented by formula (1), and having a boiling point of 205 to 255° C. and a viscosity of less than 5 mm2/s (25° C.). This cosmetic has a light touch, a good spread, and excellent water repellency, forms a uniform cosmetic film, can achieve a feeling of use without a strong oily feeling, and has stability over time and cosmetic persistence when a variety of oil such as a silicone, hydrocarbon oil, and ester, an organic ultraviolet absorber, or an oily component being solid at 25° C. is mixed. (Wherein R1 is a monovalent hydrocarbon group having 2 or 3 carbon atoms, R2, R3, R4, R5, and R6 are each independently a monovalent hydrocarbon group having 1 to 3 carbon atoms, “a” is a positive number satisfying 0<a<4, and “b” and “c” are each independently a number of 0 to 3, provided that (a+b+c) <4.

Abstract: The present invention relates to composition for styling hair comprising: (a) a first phase comprising: at least one alkoxysilane having at least one solubilizing functional group and at least one amino substituent; at least one water-soluble metal salt; at least one acidifying agent; and at least one cosmetically acceptable carrier comprising water; and (b) a second phase comprising: at least one silsesquioxane resin and at least one volatile solvent. The present invention also relates to methods of styling hair.

Abstract: A cosmetic including an acryl silicone copolymer having a (meth)acrylic chain in the main chain and a structure containing at least a silicone macromonomer shown by the following general formula (1) as the monomer unit (the acryl silicone copolymer has a refractive index of 1.47 or more). A novel glossy cosmetic that is free from tautness or stiffness unlike previous silicone resin coatings, excellent in feeling of use, adherence, and flexibility, as well as good in effect for preventing color transfer.

Abstract: A method of treating a skin condition resulting from exposure to pollution or free radicals is disclosed. The method can include topically applying to skin having the skin condition a composition comprising an effective amount of an extract of Diospyros mespiliformis leaf to reduce oxidative damage in the skin having the skin condition.

Abstract: A method of treating skin is disclosed. The method can include topically applying to skin an effective amount of a composition that includes water, a Crithmum maritimum extract, and an Ulva lactuca extract.

Abstract: The present invention relates generally to methods of use and compositions useful for treating skin to reduce the appearance of wrinkles, moisturize skin, lighten skin, reduce inflammation, increase skin firmness, or increase skin elasticity. The composition can include 20 wt. % to 45 wt. % light mineral oil, 0.1 wt. % to 5 wt. % Persea gratissima (avocado) oil, 0.1 wt. % to 5% wt. % Olea europaea (olive) fruit oil, 0.1 wt. % to 5 wt. % Argania spinosa kernel oil. 0.1 wt. % to 10 wt. % Limnanthes alba (meadowfoam) seed oil, 0.1 wt. % to 5 wt. % hybrid sunflower oil, 0.01 wt. % to 5 wt. % Crambe abyssinica seed oil, and 0.01 wt. % to 5% w/w of Daucus carota sativa (carrot) root extract.

Abstract: The invention relates to a topical composition comprising an extract of Tiger lily (Lilium tigrinum) enriched in low molecular weight RNA. The invention also relates to a method of cosmetic care including the topical application a composition comprising an extract of Tiger lily (Lilium tigrinum) in a physiologically acceptable medium, in order to reduce skin signs of aging and photo-aging. The invention is also directed to a cosmetic method of treatment to improve cell viability, to improve cell protection against particulate matter and against DNA damages, and to reduce cellular senescence.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and an antagonist of an opioid receptor, an inverse agonist of an opioid receptor, or a prodrug thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of the effects of acute opioid overdose, or the use of such a film in reducing the risk of opioid abuse.

Abstract: The present invention relates to a parenteral dosage form comprising a) a ready-to-infuse, stable aqueous solution comprising diltiazem or its pharmaceutically acceptable salt, pH adjusting agent to provide a pH in the range of 3 to 5 and ethanol, and b) an infusion container filled with said aqueous solution.

Abstract: The present technology relates to depots for the treatment of postoperative pain via sustained, controlled release of a therapeutic agent. In some embodiments, the depot may comprise a therapeutic region comprising an analgesic, and a control region comprising a bioresorbable polymer and a releasing agent mixed with the polymer. The releasing agent may be configured to dissolve when the depot is placed in vivo to form diffusion openings in the control region. The depot may be configured to be implanted at a treatment site in vivo and, while implanted, release the therapeutic agent at the treatment site for no less than 3 days.

Abstract: The present disclosure describes a vaginal system comprising segesterone acetate and ethinyl estradiol configured for thirteen 28-day product-use cycles that is compatible with male condoms comprising natural rubber latex, polyisoprene, or polyurethane and a method of providing birth control using the vaginal system wherein a secondary contraception is employed when the vaginal system is removed or expelled from the vagina for specified amounts of time during any of the product-use cycles.

Abstract: The present disclosure describes a vaginal system comprising segesterone acetate and ethinyl estradiol configured for thirteen 28-day product-use cycles that is compatible with male condoms comprising natural rubber latex, polyisoprene, or polyurethane and a method of providing birth control using the vaginal system wherein a secondary contraception is employed when the vaginal system is removed or expelled from the vagina for specified amounts of time during any of the product-use cycles.

Abstract: The present disclosure describes a vaginal system comprising segesterone acetate and ethinyl estradiol configured for thirteen 28-day product-use cycles that is compatible with male condoms comprising natural rubber latex, polyisoprene, or polyurethane and a method of providing birth control using the vaginal system wherein a secondary contraception is employed when the vaginal system is removed or expelled from the vagina for specified amounts of time during any of the product-use cycles.

Abstract: Disclosed herein are methods for treating an individual diagnosed with ABC-DLBCL. The methods include administering to the individual an inhibitor of Bruton's tyrosine kinase (Btk).

Abstract: Disclosed is a system and method of treatment which provides a direct response to the treatment of pneumonia as related to infections using a powder comprising a polyiodide resin with broad spectrum bactericidal, fungicidal and virucidal properties. When the powder is applied directly to the lungs of a mammal an immediate contact kill of protozoa, bacteria, fungi and viruses that cause respiratory tract infections affecting the lungs of a mammal takes place.

Abstract: The present invention provides pharmaceutical composition of immunosuppressive agent in oral suspension dosage form. The oral suspension composition comprises of immunosuppressive agent with other pharmaceutical excipients such as vehicle, suspending agent, solvent or cosolvent, preservative, sweetener, antifoaming agent, wetting agent, buffering agent and flavouring agent. The present invention oral suspension having improved stability, palatability with high dose of active ingredient. The present invention provides oral suspension with flavor that has masked bitter taste of the drug and eliminates difficulty of administration. Further, the present invention also provides a convenient, easy process for preparation thereof.

Abstract: The disclosure is directed to methods related to creatinine, for example, a method for its safe administration to a human, a method for using creatinine to improve the bioavailability of creatine, and a metn.

Abstract: The present invention relates to a stable liquid pharmaceutical composition of pemetrexed for parenteral administration. The invention provides composition comprising pemetrexed diacid, an organic amine and cyclodextrin. The composition may further comprise an inert gas. The composition can be ready to use infusion solution of pemetrexed diacid or liquid concentrate formulation to be diluted before administration to the patient. The present invention further relates to a process for manufacturing the compositions as well as use of the compositions of the invention for the treatment of malignant pleural mesothelioma and non-small cell lung cancer.

Abstract: Provided are compositions and nanoparticle formulations that may be used, e.g., to deliver a therapeutic compound to a subject. In some embodiments, the nanoparticles may be used to deliver one or more chemotherapeutic agents to treat a cancer such, e.g., as a pancreatic ductal adenocarcinoma.

Abstract: The present invention provides liposomes comprising a lipid bilayer and a polymer-conjugated lipid, wherein said polymer-conjugated lipid is incorporated into said lipid bilayer. The present invention also provides methods of producing the liposomes as well as a method of delivering a nucleic acid to a subject comprising the step of administering said nucleic acid encapsulated in a mixed liposome, a method for performing diagnostic imaging in a subject, comprising the step of administering a diagnost-ic agent encapsulated in a mixed liposome, and methods for treating, inhibiting, or suppressing a pathological condition in a subject comprising administering to said subject a mixed liposome.

Abstract: The disclosure provides methods for preparation of carbohydrate replacement therapies (CRT) that include nanocarriers of carbohydrates and glycolipids for pharmaceutical delivery to cell interior, endoplasmic reticulum, and Golgi for treating CDG type I and CDG type II diseases as well as other metabolic disorders.

Abstract: The present disclosure relates to methods for preparing RNA lipoplex particles for delivery of RNA to target tissues after parenteral administration, in particular after intravenous administration, and compositions comprising such RNA lipoplex particles. The present disclosure also relates to methods which allow preparing RNA lipoplex particles in an industrial GMP-compliant manner. Furthermore, the present disclosure relates to methods and compositions for storing RNA lipoplex particles without substantial loss of the product quality and, in particular, without substantial loss of RNA activity.

Abstract: Capreomycin sulfate and CPZEN-45, which act in non-identical manners to treat tuberculosis infection, are combined into particles by spray drying thereby giving an intimate mixture for combination drug therapy. The spray dried combination powder is prepared in an aerodynamic particle size range (such as 1-5 ?m) suitable for pulmonary delivery when delivered from an inhaler.

Abstract: Instead of generating immune responses to several HIV proteins and risk over activating more CD4+ T cells (easy targets for HIV-1 infection) as current candidate vaccines try to do, a lower magnitude, narrowly focused, well maintained virus specific CD8+ T cell response to multiple subtypes should destroy and eliminate a few founder viruses without inducing inflammatory responses that may activate more CD4+ T cells and provide more targets for HIV-1 virus infection. Specifically, described herein is a method that focuses the immune response to the 12 protease cleavage sites.

Abstract: The present invention relates to novel pharmaceutical formulations which have controlled, delayed release of active ingredient, and to a process for the preparation of such formulations. The invention additionally relates to the use of these novel pharmaceutical administration forms as medicaments for the treatment of diseases which require delayed release of the active ingredient, such as hypertension, or asthmatic diseases.

Abstract: Improved oral dosage forms of methyl hydrogen fumarate and prodrugs thereof are disclosed. Methods of treating diseases such as multiple sclerosis and psoriasis using such dosage forms are also disclose.

Abstract: A pharmaceutical carrier (20) comprises a lid part (22) and a bottom part (24), wherein at least one of the lid part (22) and the bottom part (24) has a first wall section (26, 30) with a thickness of 180-250 ?m, preferably 185-225 ?m, even more preferably 190-220 ?m, and most preferably about 215 ?m, and a second wall section (28, 32) with a thickness of 350-450 ?m, preferably 375-425 ?m, more preferably 390-410 ?m, and most preferably about 400 ?m. The first wall section (26) of the lid part (22) defines an entire top portion of the lid part (22). Alternatively or additionally thereto, the first wall section (30) of the bottom part (24) defines an entire bottom portion of the bottom part (24).